Amgen Inc

NASDAQ:AMGNUnited States

Yesterday

Show headlines and story abstract

• Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer, from 20 hours ago by MT Newswires

  20 hours ago by MT Newswires
  Companies Mentioned: AMGN
  04:43 PM EDT, 06/14/2024 (MT Newswires) -- Amgen (AMGN) said late Friday the US Food and Drug Administration has cleared Blincyto to treat adults and children one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor ac...

• DJ Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto, from 20 hours ago by Dow Jones

  20 hours ago by Dow Jones
  Companies Mentioned: AMGN
  
  By Sabela Ojea
  
  Amgen said the Food and Drug Administration has approved Blincyto to treat an aggressive type of blood cancer.
  
  The biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
  

• FDA APPROVES BLINCYTO(R) (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE, from 20 hours ago by Dow Jones

  20 hours ago by Dow Jones
  Companies Mentioned: AMGN
  
  This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the performance of Otezla(R) (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the Horizon Therapeutics plc acquisition (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), and any projected impacts from the Horizon acquisition on our acquisition related expenses going forward, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
  

• DJ Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game. -- Barrons.com, from 22 hours ago by Dow Jones

  22 hours ago by Dow Jones
  Companies Mentioned: GILD, LLY, NVO, AMGN
  
  By Jacob Sonenshine
  
  Gilead Sciences stock was climbing Friday on hopes that it would get into the obesity-drug game.
  
  GLP-1s, the technical name for the popular obesity drugs, has been one of the biggest drivers of pharmaceutical stocks in recent months. Have one, and there's a good chance your stock is higher; don't have one and it's difficult to get investors interested.
  

• Sector Update: Health Care Stocks Softer Friday Afternoon, from 23 hours ago by MT Newswires

  23 hours ago by MT Newswires
  Companies Mentioned: AMGN, FOXO, GANX
  02:03 PM EDT, 06/14/2024 (MT Newswires) -- Health care stocks eased Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both shedding about 0.2%. The iShares Biotechnology ETF (IBB) declined 0.8%. In c...